Mar 05, 2024 9:15am EST MyMD Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement for Continued Listing
Feb 13, 2024 11:45am EST MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
Dec 06, 2023 9:15am EST MyMD Pharmaceuticals Plans FDA-Cleared Phase 2 Clinical Trial of MYMD-1 in Rheumatoid Arthritis
Oct 04, 2023 7:30am EDT MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
Aug 14, 2023 8:30am EDT FDA Accepts MyMD Pharmaceuticals’ Investigational New Drug Application (IND) for Phase 2 Study of oral TNF-α inhibitor MYMD-1® in Rheumatoid Arthritis (RA)
Aug 02, 2023 8:30am EDT MyMD Pharmaceuticals to Hold Conference Call Today to Discuss Phase 2 Trial Results
Jul 31, 2023 9:00am EDT MyMD Pharmaceuticals Reports Statistically Significant Positive Topline Phase 2 Results for Next Generation Oral TNF-α Inhibitor MYMD-1® in Sarcopenia/Age-Related Frailty
Apr 12, 2023 8:30am EDT MyMD Pharmaceuticals® Provides Dosing Update on Phase 2 Multi-Center Clinical Trial of MYMD-1® as a Therapy for Delaying Aging and Extending Healthy Lifespan
Mar 20, 2023 8:55am EDT MyMD Pharmaceuticals® and Charles River Present Positive Data for Next Generation, Oral TNF-α Inhibitor MYMD-1® in Rheumatoid Arthritis
Mar 08, 2023 8:30am EST MyMD Joins LOT Network in Effort to Protect Company and Shareholders from Patent Trolls